Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2008

01-09-2008 | Preclinical Study

Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2

Authors: Ferdinando Mannello, Wenyi Qin, Weizhu Zhu, Laura Fabbri, Gaetana A. Tonti, Edward R. Sauter

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Login to get access

Abstract

Arachidonic acid, a bioactive molecule metabolized into prostaglandins and leukotrienes, contributes to cellular proliferation and tumor progression. Group IIa secretory phospholipase A2 (sPLA2-IIa) can facilitate arachidonate release from cellular phospholipids, suggesting its involvement in tumor evolution. Analysis of breast nipple aspirate fluid (NAF), a noninvasive research tool, allows the identification of biomarkers of breast cancer. We sought to determine whether sPLA2-IIa expression might be related to breast cancer development or progression. sPLA2-IIa expression was evaluated in NAF samples from 110 women (57 women with and 53 without breast cancer) using ELISA and western blotting; ultrastructural immunolocalization was performed in epithelial cells floating in NAF. Immunocytochemistry revealed that sPLA2-IIa is a constitutive intracellular protein suggesting that breast ductal cells synthesize and secrete the 14 kDa protein in NAF. Among all 110 subjects, sPLA2-IIa expression was significantly increased both in NAF and within ductal epithelial cells from cancer containing breasts. While in healthy women menopausal status did not influence sPLA2-IIa expression (P = 0.457), among patients with breast cancer there was a significant down-regulation in postmenopausal subjects (P < 0.0001). Moreover, sPLA2-IIa concentration in NAF from breast cancer patients was positively correlated with tumor stage (r 2 = 0.979, P = 0.0012), suggesting an active secretion/accumulation of the enzyme in NAF based on tumor burden. sPLA2-IIa activity may serve a dual role in breast carcinogenesis, beneficial in its release of arachidonate and detrimental in the metabolic conversion of arachadonic acid into prostaglandins and leukotrienes.
Literature
1.
2.
Six DA, Dennis EA (2000) The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochem Biophys Acta 1488:1–19PubMed
3.
4.
Balsinde J, Winstead MV, Dennis EA (2002) Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett 531:2–6PubMedCrossRef
5.
Touqui L (2001) Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med 1:739–754PubMedCrossRef
6.
Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, Miyamoto S, Ogawa H, Takazoe K, Yasue H (2000) Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 86:718–722PubMedCrossRef
7.
Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES (1997) Secretory phospholipase PLA2 g2a confer resistance to intestinal tumorigenesis. Nat Genet 17:88–91PubMedCrossRef
8.
Murata K, Egami H, Kiyohara H, Oshima S, Kurizaki T, Ogawa M (1993) Expression of group-II phospholipase A2 in malignant and non-malignant human gastric mucosa. Br J Cancer 68:103–111PubMed
9.
Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J, Chan ASY, Li R, Law S, Troyanskaya OG, Tu IP, Wong J, So S, Botstein D, Brown PO (2002) Phospholipase A2 group IIa expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci 99:16203–16208PubMedCrossRef
10.
Kiyohara H, Egami H, Kako H, Shibata Y, Murata K, Ohshima S, Sei K, Suko S, Kurano R, Ogawa M (1993) Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas. Int J Pancreatol 13:49–57PubMed
11.
Kashiwagi M, Friess H, Uhl W, Berberat P, Abou-Shady M, Martignoni M, Anghelacopoulos SE, Zimmermann A, Buchler MW (1999) Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influences prognosis. Gut 45:605–612PubMedCrossRef
12.
Ying Z, Tojo H, Komatsubara T, Nagakawa M, Inada M, Kawata S, Matsuzawa Y, Okamoto M (1994) Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma. Biochim Biophys Acta 1226:201–205PubMed
13.
Kennedy BP, Soravia C, Moffat J, Xia L, Hiruki T, Collins S, Gallinger S, Bapat B (1998) Overexpression of the non-pancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res 58:500–503PubMed
14.
Graff JR, Konicek BW, Deddens JA, Chedid M, Hurst BM, Colligan B, Neubauer BL, Carter HW, Carter JH (2001) Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 7:3857–3861PubMed
15.
Yamashita S, Yamashita J, Ogawa M (1994) Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69:1166–1170PubMed
16.
Yamashita S, Yamashita J, Sakamoto K, Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K, Ogawa M (1993) Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer 71:3058–3064PubMedCrossRef
17.
Yamashita J, Ogawa M, Sakai K (1995) Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117:601–608PubMedCrossRef
18.
Hatala MA, Rayburn J, Rose DP (1993) Characterization of phospholipase A2 activity in MDA-MB-435 human breast cancer cells. Cancer Lett 72:31–37PubMedCrossRef
19.
Yamashita S, Ogawa M, Sakamoto K, Abe T, Arakawa H, Yamashita J (1994) Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta 228:91–99PubMedCrossRef
20.
Brueseke TJ, Bell JD (2006) A new hat for an old enzyme: waste management. Biochim Biophys Acta 1761:1270–1279PubMed
21.
Fuentes L, Hernandez M, Nieto ML, Crespo MS (2002) Biological effects of group IIA secreted phospholipase A2. FEBS Lett 531:7–11PubMedCrossRef
22.
Chun KS, Surh YJ (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68:1089–1100PubMedCrossRef
23.
Meric JP, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP (2006) Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59:51–64PubMedCrossRef
24.
25.
26.
Cuendet M, Pezzuto JM (2000) The role of cyclooxygenase and lipooxygenase in cancer chemoprevention. Drug Metabol Drug Interact 17:109–157PubMed
27.
Howe LR, Dannenberg AJ (2003) COX-2 inhibitors for the prevention of breast cancer. J Mammary Gland Biol Neoplasia 8:31–43PubMedCrossRef
28.
Larkins TL, Nowell M, Singh S, Sanford GL (2006) Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6:181PubMedCrossRef
29.
30.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMed
31.
Sauter ER, Ross E, Daly M, Klein-Szanto A, Engstrom PF, Sorling A, Malick J, Ehaya H (1997) Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 76:494–501PubMed
32.
Alexander H, Stegner AL, Wagner-Mann C, Dubois GC, Alexander S, Sauter ER (2004) Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 10:7500–7510PubMedCrossRef
33.
Mannello F, Malatesta M, Sebastiani M, Battistelli S, Gazzanelli G (1999) Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids. Clin Chem 45:2263–2266PubMed
34.
Qin W, Zhu W, Wagner-Mann C, Sauter ER (2003) Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Ann Surg Oncol 10:948–953PubMedCrossRef
35.
Mannello F, Sebastiani M (2003) Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids. Clin Chem 49:1546–1550PubMedCrossRef
36.
Mannello F, Tonti GAM, Pagliarani S, Benedetti S, Canestrari F, Zhu W, Qin W, Sauter ER (2007) The 8-epimer of prostaglandin F2α, a marker of lipid peroxidation and oxidative stress, is decreased in the nipple aspirate fluids of women with breast cancer. Int J Cancer 120:1971–1976PubMedCrossRef
37.
Fulton AM, Gimotty P, Alonsozana E, Dorsey R, Kundu N (2000) Elevated prostaglandin E2 (PGE2) levels in human breast cancer are associated with poor long-term survival. Proc Am Assn Cancer Res 41:3660A
38.
Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27PubMedCrossRef
39.
Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin 56:37–47PubMedCrossRef
40.
Nevalainen TJ, Kortesuo PT, Rintala E, Marki F (1992) Immunochemical detection of group I and group II phospholipase A2 in human serum. Clin Chem 38:1824–1829PubMed
41.
Mannello F, Malatesta M, Sebastiani M, Battistelli S, Gazzanelli G (1999) Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids. Clin Chem 45:2263–2266PubMed
42.
Pechoux C, Boisgard R, Chanat E, Lavialle F (2005) Ca(2+)-independent phospholipase A2 participates in the vesicular transport of milk proteins. Biochim Biophys Acta 1743:317–329PubMedCrossRef
43.
Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95:681–686PubMedCrossRef
44.
Enomoto A, Murakami M, Kudo I (2000) Internalization and degradation of Type IIA phospholipase A(2) in mast cells. Biochem Biophys Res Commun 276:667–672PubMedCrossRef
45.
Thomas W, Coen N, Faherty S, Flatharta CO, Harvey BJ (2006) Estrogen induces phospholipase A2 activation through ERK to mobilize intracellular calcium in MCF-7 cells. Steroids 71:256–265PubMedCrossRef
46.
Periwal SB, Farooq A, Bhargava VL, Bhatla N, Vij U, Murugesan K (1996) Effect of hormones and anti-hormones on phospholipase A2 activity in human endometrial stromal cells. Prostaglandins 51:191–201PubMedCrossRef
47.
Farina MG, Billi S, Leguizamon G, Weissmann C, Guadagnoli T, Ribeiro ML, Franchi AM (2007) Secretory and cytosolic phospholipase A2 activities and expression are regulated by oxytocin and estradiol during labor. Reproduction 134:355–364PubMedCrossRef
48.
Kurusu S, Ishii S, Kawaminami M (2007) Changes in Rat uterine and cervicale phospholipase A2 activity following progesterone agonist and antagonist administration at term. J Reprod Dev 53:345–350PubMedCrossRef
49.
Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81:146–156PubMedCrossRef
50.
Dong Q, Patel M, Scott KF, Graham GG, Russell PJ, Sved P (2006) Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 240:9–16PubMedCrossRef
51.
Taylor PM, Woodfield RJ, Hodgkin MN, Pettitt TR, Martin A, Kerr DJ, Wakelam MJ (2002) Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A2 and 5-lipoxygenase catalyzed pathway. Oncogene 21:5765–5772PubMedCrossRef
52.
Hernandez M, Burillo SL, Crespo MS, Nieto ML (1998) Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1. J Biol Chem 273:606–612PubMedCrossRef
53.
Reddy KB, Glaros S (2007) Inhibition of MAP kinase activity suppresses estrogen-induced breast tumor growth both in vivo and in vitro. Int J Oncol 30:971–975PubMed
54.
Cuenda A, Rousseau S (2007) p-38 MAP-kinase pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773:1358–1375PubMedCrossRef
55.
Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871–1875PubMedCrossRef
56.
Wolf I, O’Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tay HH, Karlan BY, Koeffler HP (2006) 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66:7818–7823PubMedCrossRef
57.
Diaz-Cruz ES, Brueggemeimer RW (2006) Interrelationship between cyclooxygenase and aromatase: unraveling the relevance of cyclooxygenase inhibitor in breast cancer. Anticancer Agents Med Chem 6:221–232PubMedCrossRef
58.
Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T (2005) Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89:215–220PubMedCrossRef
59.
Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE (2005) Celecoxib analogues disrupt Akt signaling, which is commonly activated in prim ary breast tumors. Breast Cancer Res 7:796–807CrossRef
60.
Barnes NL, Warneberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ (2007) Cyclooxygenase-2 inhibition: effects on tumor growth cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96:575–582PubMedCrossRef
61.
Sauter ER, Qin W, Schlatter L, Hewett J, Flynn TJ (2006) Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk popst-menopausal women and women with breast cancer. BMC Cancer 6:248PubMedCrossRef
62.
Natarajan R, Nadler J (1998) Role of lipooxygenase in breast cancer. Front Biosci 3:81–88
63.
Furstenberger G, Krieg P, Muller-Decker K, Habenicht AJ (2006) What are cyclooxygenases and lipooxygenases doing in the driver’s seat of carcinogenesis?. Int J Cancer 119:2247–2254PubMedCrossRef
64.
Chamras H, Ardashian A, Heber D, Glaspy JA (2002) Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem 13:711–716PubMedCrossRef
65.
Levine L (2004) Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells. BMC Pharmacol 4:15PubMedCrossRef
66.
Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL (2001) Five lipooxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 15:2007–2009PubMed
67.
Leone S, Ottani A, Bertolini A (2007) Dual acting anti-inflammatory drugs. Curr Top Med Chem 7:265–275PubMedCrossRef
68.
Cakir Y, Plummer HK III, Tithof PK, Schuller HM (2002) Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 21:153–157PubMed
69.
Covey TM, Edes K, Fitzpatrik FA (2007) Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppression. Oncogene 26:5784–5792PubMedCrossRef
70.
Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D’Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis GA (2004) Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 10:4062–4067PubMedCrossRef
71.
Canney PA, Machin MA, Curto J (2006) A feasibility study of the efficacy and tolerability of the combination of Exemestane with the Cox-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer 42:2751–2756PubMedCrossRef
72.
Petrakis NL (1986) Physiologic, biochemical, and cytological aspects of nipple aspirate fluids. Breast Cancer Res Treat 8:7–19PubMedCrossRef
73.
Reids RC (2005) Inhibitors of secretory phospholipase A2 group IIA. Curr Med Chem 12:3011–3026CrossRef
Metadata
Title
Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2
Authors
Ferdinando Mannello
Wenyi Qin
Weizhu Zhu
Laura Fabbri
Gaetana A. Tonti
Edward R. Sauter
Publication date
01-09-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9779-1

Other articles of this Issue 2/2008

Breast Cancer Research and Treatment 2/2008 Go to the issue

Preclinical Study

Seasonal modulation of post-resection breast cancer metastasis

Preclinical Study

Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor

Epidemiology

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100

Preclinical Study

2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique

Invited Commentary

Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

Clinical Trial

Does computer-aided detection (CAD) contribute to the performance of digital mammography in a self-referred population?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits